{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T15:16:20Z","timestamp":1785251780429,"version":"3.55.0"},"reference-count":97,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:00Z","timestamp":1657670400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T00:00:00Z","timestamp":1657670400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100002322","name":"Coordena\u00e7\u00e3o de Aperfei\u00e7oamento de Pessoal de N\u00edvel Superior","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Psychiatry Clin Neurosci"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1007\/s00406-022-01460-2","type":"journal-article","created":{"date-parts":[[2022,7,13]],"date-time":"2022-07-13T09:03:38Z","timestamp":1657703018000},"page":"129-155","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The effects of ketamine and classic hallucinogens on neurotrophic and inflammatory markers in unipolar treatment-resistant depression: a systematic review of clinical trials"],"prefix":"10.1007","volume":"273","author":[{"given":"Giordano Novak","family":"Rossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime E. C.","family":"Hallak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Glen","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serdar M.","family":"Dursun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2388-4745","authenticated-orcid":false,"given":"Rafael G.","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,13]]},"reference":[{"key":"1460_CR1","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1177\/2045125312445469","volume":"2","author":"E Penn","year":"2012","unstructured":"Penn E, Tracy DK (2012) The drugs don\u2019t work? Antidepressants and the current and future pharmacological management of depression. Ther Adv Psychopharmacol 2:179\u2013188. https:\/\/doi.org\/10.1177\/2045125312445469","journal-title":"Ther Adv Psychopharmacol"},{"key":"1460_CR2","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1016\/s0140-6736(18)31948-2","volume":"392","author":"GS Malhi","year":"2018","unstructured":"Malhi GS, Mann JJ (2018) Depression. Lancet 392:2299\u20132312. https:\/\/doi.org\/10.1016\/s0140-6736(18)31948-2","journal-title":"Lancet"},{"key":"1460_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph15092028","author":"L Br\u00e5dvik","year":"2018","unstructured":"Br\u00e5dvik L (2018) Suicide risk and mental disorders. Int J Environ Res Public Health. https:\/\/doi.org\/10.3390\/ijerph15092028","journal-title":"Int J Environ Res Public Health"},{"key":"1460_CR4","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1016\/s0140-6736(17)32802-7","volume":"391","author":"A Cipriani","year":"2018","unstructured":"Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, Leucht S, Ruhe HG, Turner EH, Higgins JPT, Egger M, Takeshima N, Hayasaka Y, Imai H, Shinohara K, Tajika A, Ioannidis JPA, Geddes JR (2018) Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet 391:1357\u20131366. https:\/\/doi.org\/10.1016\/s0140-6736(17)32802-7","journal-title":"Lancet"},{"key":"1460_CR5","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1177\/0269881117711708","volume":"31","author":"K Feltes","year":"2017","unstructured":"Feltes K, Doorduin J, Klein HC, Ju\u00e1rez-Orozco LE, Dierckx RA, Moriguchi-Jeckel CM, de Vries EF (2017) Anti-inflammatory treatment for major depressive disorder: implications for patients with an elevated immune profile and non-responders to standard antidepressant therapy. J Psychopharmacol 31:1149\u20131165. https:\/\/doi.org\/10.1177\/0269881117711708","journal-title":"J Psychopharmacol"},{"issue":"Suppl 8","key":"1460_CR6","first-page":"17","volume":"68","author":"CB Nemeroff","year":"2007","unstructured":"Nemeroff CB (2007) Prevalence and management of treatment-resistant depression. J Clin Psychiatry 68(Suppl 8):17\u201325","journal-title":"J Clin Psychiatry"},{"key":"1460_CR7","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1080\/00048670802277206","volume":"42","author":"C Wijeratne","year":"2008","unstructured":"Wijeratne C, Sachdev P (2008) Treatment-resistant depression: critique of current approaches. Aust N Z J Psychiatry 42:751\u2013762. https:\/\/doi.org\/10.1080\/00048670802277206","journal-title":"Aust N Z J Psychiatry"},{"key":"1460_CR8","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00005-019-00543-8","volume":"67","author":"\u0141P Sza\u0142ach","year":"2019","unstructured":"Sza\u0142ach \u0141P, Lisowska KA, Cuba\u0142a WJ (2019) The influence of antidepressants on the immune system. Arch Immunol Ther Exp (Warsz) 67:143\u2013151. https:\/\/doi.org\/10.1007\/s00005-019-00543-8","journal-title":"Arch Immunol Ther Exp (Warsz)"},{"key":"1460_CR9","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1176\/appi.ajp.2012.12050648","volume":"169","author":"CH Kellner","year":"2012","unstructured":"Kellner CH, Greenberg RM, Murrough JW, Bryson EO, Briggs MC, Pasculli RM (2012) Ect in treatment-resistant depression. Am J Psychiatry 169:1238\u20131244. https:\/\/doi.org\/10.1176\/appi.ajp.2012.12050648","journal-title":"Am J Psychiatry"},{"key":"1460_CR10","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.2147\/dddt.S221437","volume":"13","author":"A Corriger","year":"2019","unstructured":"Corriger A, Pickering G (2019) Ketamine and depression: a narrative review. Drug Des Dev Ther 13:3051\u20133067. https:\/\/doi.org\/10.2147\/dddt.S221437","journal-title":"Drug Des Dev Ther"},{"key":"1460_CR11","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1177\/0269881120986422","volume":"35","author":"RG Dos Santos","year":"2021","unstructured":"Dos Santos RG, Hallak JE, Baker G, Dursun S (2021) Hallucinogenic\/psychedelic 5ht2a receptor agonists as rapid antidepressant therapeutics: evidence and mechanisms of action. J Psychopharmacol 35:453\u2013458. https:\/\/doi.org\/10.1177\/0269881120986422","journal-title":"J Psychopharmacol"},{"key":"1460_CR12","doi-asserted-by":"publisher","first-page":"204512532091665","DOI":"10.1177\/2045125320916657","volume":"10","author":"D Matveychuk","year":"2020","unstructured":"Matveychuk D, Thomas RK, Swainson J, Khullar A, MacKay MA, Baker GB, Dursun SM (2020) Ketamine as an antidepressant: overview of its mechanisms of action and potential predictive biomarkers. Ther Adv Psychopharmacol 10:2045125320916657. https:\/\/doi.org\/10.1177\/2045125320916657","journal-title":"Ther Adv Psychopharmacol"},{"key":"1460_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.jad.2019.07.076","volume":"258","author":"S Muttoni","year":"2019","unstructured":"Muttoni S, Ardissino M, John C (2019) Classical psychedelics for the treatment of depression and anxiety: a systematic review. J Affect Disord 258:11\u201324. https:\/\/doi.org\/10.1016\/j.jad.2019.07.076","journal-title":"J Affect Disord"},{"key":"1460_CR14","doi-asserted-by":"publisher","first-page":"172870","DOI":"10.1016\/j.pbb.2020.172870","volume":"190","author":"Y Wei","year":"2020","unstructured":"Wei Y, Chang L, Hashimoto K (2020) A historical review of antidepressant effects of ketamine and its enantiomers. Pharmacol Biochem Behav 190:172870. https:\/\/doi.org\/10.1016\/j.pbb.2020.172870","journal-title":"Pharmacol Biochem Behav"},{"key":"1460_CR15","doi-asserted-by":"publisher","first-page":"10544","DOI":"10.1523\/jneurosci.3007-12.2013","volume":"33","author":"M Kometer","year":"2013","unstructured":"Kometer M, Schmidt A, J\u00e4ncke L, Vollenweider FX (2013) Activation of serotonin 2a receptors underlies the psilocybin-induced effects on \u03b1 oscillations, n170 visual-evoked potentials, and visual hallucinations. J Neurosci 33:10544\u201310551. https:\/\/doi.org\/10.1523\/jneurosci.3007-12.2013","journal-title":"J Neurosci"},{"key":"1460_CR16","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/s41386-019-0324-9","volume":"44","author":"MK Madsen","year":"2019","unstructured":"Madsen MK, Fisher PM, Burmester D, Dyssegaard A, Stenb\u00e6k DS, Kristiansen S, Johansen SS, Lehel S, Linnet K, Svarer C, Erritzoe D, Ozenne B, Knudsen GM (2019) Psychedelic effects of psilocybin correlate with serotonin 2a receptor occupancy and plasma psilocin levels. Neuropsychopharmacology 44:1328\u20131334. https:\/\/doi.org\/10.1038\/s41386-019-0324-9","journal-title":"Neuropsychopharmacology"},{"key":"1460_CR17","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols DE (2016) Psychedelics. Pharmacol Rev 68:264\u2013355. https:\/\/doi.org\/10.1124\/pr.115.011478","journal-title":"Pharmacol Rev"},{"key":"1460_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/0269881120959644","volume":"35","author":"LA Jelen","year":"2021","unstructured":"Jelen LA, Young AH, Stone JM (2021) Ketamine: a tale of two enantiomers. J Psychopharmacol 35:109\u2013123. https:\/\/doi.org\/10.1177\/0269881120959644","journal-title":"J Psychopharmacol"},{"key":"1460_CR19","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1038\/mp.2017.255","volume":"23","author":"P Zanos","year":"2018","unstructured":"Zanos P, Gould TD (2018) Mechanisms of ketamine action as an antidepressant. Mol Psychiatry 23:801\u2013811. https:\/\/doi.org\/10.1038\/mp.2017.255","journal-title":"Mol Psychiatry"},{"key":"1460_CR20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s12640-012-9348-1","volume":"23","author":"LL Hurley","year":"2013","unstructured":"Hurley LL, Tizabi Y (2013) Neuroinflammation, neurodegeneration, and depression. Neurotox Res 23:131\u2013144. https:\/\/doi.org\/10.1007\/s12640-012-9348-1","journal-title":"Neurotox Res"},{"key":"1460_CR21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.neubiorev.2019.04.002","volume":"102","author":"CPC Galts","year":"2019","unstructured":"Galts CPC, Bettio LEB, Jewett DC, Yang CC, Brocardo PS, Rodrigues ALS, Thacker JS, Gil-Mohapel J (2019) Depression in neurodegenerative diseases: common mechanisms and current treatment options. Neurosci Biobehav Rev 102:56\u201384. https:\/\/doi.org\/10.1016\/j.neubiorev.2019.04.002","journal-title":"Neurosci Biobehav Rev"},{"key":"1460_CR22","doi-asserted-by":"publisher","first-page":"179","DOI":"10.2147\/jir.S141033","volume":"11","author":"SW Jeon","year":"2018","unstructured":"Jeon SW, Kim YK (2018) The role of neuroinflammation and neurovascular dysfunction in major depressive disorder. J Inflamm Res 11:179\u2013192. https:\/\/doi.org\/10.2147\/jir.S141033","journal-title":"J Inflamm Res"},{"key":"1460_CR23","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/j.ebiom.2019.10.063","volume":"50","author":"W Nowak","year":"2019","unstructured":"Nowak W, Grendas LN, Sanmarco LM, Estecho IG, Arena \u00c1R, Eberhardt N, Rodante DE, Aoki MP, Daray FM, Carrera Silva EA, Errasti AE (2019) Pro-inflammatory monocyte profile in patients with major depressive disorder and suicide behaviour and how ketamine induces anti-inflammatory m2 macrophages by nmdar and mtor. EBioMedicine 50:290\u2013305. https:\/\/doi.org\/10.1016\/j.ebiom.2019.10.063","journal-title":"EBioMedicine"},{"key":"1460_CR24","doi-asserted-by":"publisher","first-page":"e51197","DOI":"10.1371\/journal.pone.0051197","volume":"7","author":"N Kajitani","year":"2012","unstructured":"Kajitani N, Hisaoka-Nakashima K, Morioka N, Okada-Tsuchioka M, Kaneko M, Kasai M, Shibasaki C, Nakata Y, Takebayashi M (2012) Antidepressant acts on astrocytes leading to an increase in the expression of neurotrophic\/growth factors: differential regulation of fgf-2 by noradrenaline. PLoS\u00a0One 7:e51197. https:\/\/doi.org\/10.1371\/journal.pone.0051197","journal-title":"PLoS\u00a0One"},{"key":"1460_CR25","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/nn1971","volume":"10","author":"K Martinowich","year":"2007","unstructured":"Martinowich K, Manji H, Lu B (2007) New insights into bdnf function in depression and anxiety. Nat Neurosci 10:1089\u20131093. https:\/\/doi.org\/10.1038\/nn1971","journal-title":"Nat Neurosci"},{"key":"1460_CR26","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.biopsych.2008.05.005","volume":"64","author":"S Sen","year":"2008","unstructured":"Sen S, Duman R, Sanacora G (2008) Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry 64:527\u2013532. https:\/\/doi.org\/10.1016\/j.biopsych.2008.05.005","journal-title":"Biol Psychiatry"},{"key":"1460_CR27","doi-asserted-by":"publisher","first-page":"4647","DOI":"10.1073\/pnas.0610282104","volume":"104","author":"JL Warner-Schmidt","year":"2007","unstructured":"Warner-Schmidt JL, Duman RS (2007) Vegf is an essential mediator of the neurogenic and behavioral actions of antidepressants. Proc Natl Acad Sci USA 104:4647\u20134652. https:\/\/doi.org\/10.1073\/pnas.0610282104","journal-title":"Proc Natl Acad Sci USA"},{"key":"1460_CR28","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jad.2015.05.067","volume":"184","author":"CD Wiener","year":"2015","unstructured":"Wiener CD, de Mello FS, Pedrotti Moreira F, Bittencourt G, de Oliveira JF, Lopez Molina M, Jansen K, de Mattos Souza LD, Rizzato Lara D, Portela LV, da Silva RA, Oses JP (2015) Serum levels of nerve growth factor (ngf) in patients with major depression disorder and suicide risk. J Affect Disord 184:245\u2013248. https:\/\/doi.org\/10.1016\/j.jad.2015.05.067","journal-title":"J Affect Disord"},{"key":"1460_CR29","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.bbi.2019.06.001","volume":"81","author":"R Hou","year":"2019","unstructured":"Hou R, Ye G, Liu Y, Chen X, Pan M, Zhu F, Fu J, Fu T, Liu Q, Gao Z, Baldwin DS, Tang Z (2019) Effects of ssris on peripheral inflammatory cytokines in patients with generalized anxiety disorder. Brain Behav Immun 81:105\u2013110. https:\/\/doi.org\/10.1016\/j.bbi.2019.06.001","journal-title":"Brain Behav Immun"},{"key":"1460_CR30","doi-asserted-by":"publisher","first-page":"172837","DOI":"10.1016\/j.pbb.2019.172837","volume":"188","author":"S Deyama","year":"2020","unstructured":"Deyama S, Duman RS (2020) Neurotrophic mechanisms underlying the rapid and sustained antidepressant actions of ketamine. Pharmacol Biochem Behav 188:172837. https:\/\/doi.org\/10.1016\/j.pbb.2019.172837","journal-title":"Pharmacol Biochem Behav"},{"key":"1460_CR31","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/mp.2017.144","volume":"22","author":"M Song","year":"2017","unstructured":"Song M, Martinowich K, Lee FS (2017) Bdnf at the synapse: why location matters. Mol Psychiatry 22:1370\u20131375. https:\/\/doi.org\/10.1038\/mp.2017.144","journal-title":"Mol Psychiatry"},{"key":"1460_CR32","doi-asserted-by":"publisher","first-page":"g7647","DOI":"10.1136\/bmj.g7647","volume":"350","author":"L Shamseer","year":"2015","unstructured":"Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA (2015) Preferred reporting items for systematic review and meta-analysis protocols (prisma-p) 2015: elaboration and explanation. BMJ 350:g7647. https:\/\/doi.org\/10.1136\/bmj.g7647","journal-title":"BMJ"},{"key":"1460_CR33","doi-asserted-by":"publisher","first-page":"698633","DOI":"10.3389\/fnins.2021.698633","volume":"15","author":"H Jiang","year":"2021","unstructured":"Jiang H, Veldman ER, Tiger M, Ekman CJ, Lundberg J, Svenningsson P (2021) Plasma levels of brain-derived neurotrophic factor and S100B in relation to antidepressant response to ketamine. Front Neurosci 15:698633. https:\/\/doi.org\/10.3389\/fnins.2021.698633","journal-title":"Front Neurosci"},{"key":"1460_CR34","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.jad.2020.11.011","volume":"280","author":"GC Medeiros","year":"2021","unstructured":"Medeiros GC, Greenstein D, Kadriu B, Yuan P, Park LT, Gould TD, Zarate CA Jr (2021) Treatment of depression with ketamine does not change plasma levels of brain-derived neurotrophic factor or vascular endothelial growth factor. J Affect Disord 280:136\u2013139. https:\/\/doi.org\/10.1016\/j.jad.2020.11.011","journal-title":"J Affect Disord"},{"key":"1460_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41380-020-00878-1","author":"A Mkrtchian","year":"2020","unstructured":"Mkrtchian A, Evans JW, Kraus C, Yuan P, Kadriu B, Nugent AC, Roiser JP, Zarate CA (2020) Ketamine modulates fronto-striatal circuitry in depressed and healthy individuals. Mol Psychiatry. https:\/\/doi.org\/10.1038\/s41380-020-00878-1","journal-title":"Mol Psychiatry"},{"key":"1460_CR36","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.jad.2015.06.033","volume":"186","author":"AP Allen","year":"2015","unstructured":"Allen AP, Naughton M, Dowling J, Walsh A, Ismail F, Shorten G, Scott L, McLoughlin DM, Cryan JF, Dinan TG, Clarke G (2015) Serum bdnf as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: a comparison of ketamine and ect. J Affect Disord 186:306\u2013311. https:\/\/doi.org\/10.1016\/j.jad.2015.06.033","journal-title":"J Affect Disord"},{"key":"1460_CR37","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.psychres.2018.08.078","volume":"269","author":"MH Chen","year":"2018","unstructured":"Chen MH, Li CT, Lin WC, Hong CJ, Tu PC, Bai YM, Cheng CM, Su TP (2018) Rapid inflammation modulation and antidepressant efficacy of a low-dose ketamine infusion in treatment-resistant depression: a randomized, double-blind control study. Psychiatry Res 269:207\u2013211. https:\/\/doi.org\/10.1016\/j.psychres.2018.08.078","journal-title":"Psychiatry Res"},{"key":"1460_CR38","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.3389\/fpsyg.2019.01234","volume":"10","author":"RN de Almeida","year":"2019","unstructured":"de Almeida RN, Galv\u00e3o ACM, da Silva FS, Silva E, Palhano-Fontes F, Maia-de-Oliveira JP, de Ara\u00fajo LB, Lob\u00e3o-Soares B, Galv\u00e3o-Coelho NL (2019) Modulation of serum brain-derived neurotrophic factor by a single dose of ayahuasca: observation from a randomized controlled trial. Front Psychol 10:1234. https:\/\/doi.org\/10.3389\/fpsyg.2019.01234","journal-title":"Front Psychol"},{"key":"1460_CR39","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1017\/s1461145712000545","volume":"16","author":"WC Duncan","year":"2013","unstructured":"Duncan WC, Sarasso S, Ferrarelli F, Selter J, Riedner BA, Hejazi NS, Yuan P, Brutsche N, Manji HK, Tononi G, Zarate CA (2013) Concomitant bdnf and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int J Neuropsychopharmacol 16:301\u2013311. https:\/\/doi.org\/10.1017\/s1461145712000545","journal-title":"Int J Neuropsychopharmacol"},{"key":"1460_CR40","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1177\/0269881120936486","volume":"34","author":"NL Galv\u00e3o-Coelho","year":"2020","unstructured":"Galv\u00e3o-Coelho NL, de Menezes Galv\u00e3o AC, de Almeida RN, Palhano-Fontes F, Campos Braga I, Lob\u00e3o Soares B, Maia-de-Oliveira JP, Perkins D, Sarris J, de Araujo DB (2020) Changes in inflammatory biomarkers are related to the antidepressant effects of ayahuasca. J Psychopharmacol 34:1125\u20131133. https:\/\/doi.org\/10.1177\/0269881120936486","journal-title":"J Psychopharmacol"},{"key":"1460_CR41","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1038\/mp.2017.109","volume":"23","author":"B Kadriu","year":"2018","unstructured":"Kadriu B, Gold PW, Luckenbaugh DA, Lener MS, Ballard ED, Niciu MJ, Henter ID, Park LT, De Sousa RT, Yuan P, Machado-Vieira R, Zarate CA (2018) Acute ketamine administration corrects abnormal inflammatory bone markers in major depressive disorder. Mol Psychiatry 23:1626\u20131631. https:\/\/doi.org\/10.1038\/mp.2017.109","journal-title":"Mol Psychiatry"},{"key":"1460_CR42","doi-asserted-by":"publisher","first-page":"e1065","DOI":"10.1038\/tp.2017.31","volume":"7","author":"DD Kiraly","year":"2017","unstructured":"Kiraly DD, Horn SR, Van Dam NT, Costi S, Schwartz J, Kim-Schulze S, Patel M, Hodes GE, Russo SJ, Merad M, Iosifescu DV, Charney DS, Murrough JW (2017) Altered peripheral immune profiles in treatment-resistant depression: response to ketamine and prediction of treatment outcome. Transl Psychiatry 7:e1065. https:\/\/doi.org\/10.1038\/tp.2017.31","journal-title":"Transl Psychiatry"},{"key":"1460_CR43","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.4088\/JCP.08m04659","volume":"70","author":"R Machado-Vieira","year":"2009","unstructured":"Machado-Vieira R, Yuan P, Brutsche N, DiazGranados N, Luckenbaugh D, Manji HK, Zarate CA Jr (2009) Brain-derived neurotrophic factor and initial antidepressant response to an n-methyl-d-aspartate antagonist. J Clin Psychiatry 70:1662\u20131666. https:\/\/doi.org\/10.4088\/JCP.08m04659","journal-title":"J Clin Psychiatry"},{"key":"1460_CR44","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1017\/s1461145713001119","volume":"17","author":"CN Haile","year":"2014","unstructured":"Haile CN, Murrough JW, Iosifescu DV, Chang LC, Al Jurdi RK, Foulkes A, Iqbal S, Mahoney JJ 3rd, De La Garza R 2nd, Charney DS, Newton TF, Mathew SJ (2014) Plasma brain derived neurotrophic factor (bdnf) and response to ketamine in treatment-resistant depression. Int J Neuropsychopharmacol 17:331\u2013336. https:\/\/doi.org\/10.1017\/s1461145713001119","journal-title":"Int J Neuropsychopharmacol"},{"key":"1460_CR45","doi-asserted-by":"publisher","first-page":"e19","DOI":"10.1016\/j.biopsych.2014.06.021","volume":"77","author":"JJ Yang","year":"2015","unstructured":"Yang JJ, Wang N, Yang C, Shi JY, Yu HY, Hashimoto K (2015) Serum interleukin-6 is a predictive biomarker for ketamine\u2019s antidepressant effect in treatment-resistant patients with major depression. Biol Psychiatry 77:e19\u2013e20. https:\/\/doi.org\/10.1016\/j.biopsych.2014.06.021","journal-title":"Biol Psychiatry"},{"key":"1460_CR46","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1017\/s0033291718001356","volume":"49","author":"F Palhano-Fontes","year":"2019","unstructured":"Palhano-Fontes F, Barreto D, Onias H, Andrade KC, Novaes MM, Pessoa JA, Mota-Rolim SA, Os\u00f3rio FL, Sanches R, Dos Santos RG, T\u00f3foli LF, de Oliveira SG, Yonamine M, Riba J, Santos FR, Silva-Junior AA, Alchieri JC, Galv\u00e3o-Coelho NL, Lob\u00e3o-Soares B, Hallak JEC, Arcoverde E, Maia-de-Oliveira JP, Ara\u00fajo DB (2019) Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trial. Psychol Med 49:655\u2013663. https:\/\/doi.org\/10.1017\/s0033291718001356","journal-title":"Psychol Med"},{"key":"1460_CR47","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1038\/s41380-018-0028-2","volume":"24","author":"AC Nugent","year":"2019","unstructured":"Nugent AC, Ballard ED, Gould TD, Park LT, Moaddel R, Brutsche NE, Zarate CA Jr (2019) Ketamine has distinct electrophysiological and behavioral effects in depressed and healthy subjects. Mol Psychiatry 24:1040\u20131052. https:\/\/doi.org\/10.1038\/s41380-018-0028-2","journal-title":"Mol Psychiatry"},{"key":"1460_CR48","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jpsychires.2016.09.025","volume":"84","author":"M Park","year":"2017","unstructured":"Park M, Newman LE, Gold PW, Luckenbaugh DA, Yuan P, Machado-Vieira R, Zarate CA Jr (2017) Change in cytokine levels is not associated with rapid antidepressant response to ketamine in treatment-resistant depression. J Psychiatr Res 84:113\u2013118. https:\/\/doi.org\/10.1016\/j.jpsychires.2016.09.025","journal-title":"J Psychiatr Res"},{"key":"1460_CR49","doi-asserted-by":"publisher","first-page":"204512532092247","DOI":"10.1177\/2045125320922474","volume":"10","author":"P Glue","year":"2020","unstructured":"Glue P, Medlicott NJ, Neehoff S, Surman P, Lam F, Hung N, Hung CT (2020) Safety and efficacy of extended release ketamine tablets in patients with treatment-resistant depression and anxiety: open label pilot study. Ther Adv Psychopharmacol 10:2045125320922474. https:\/\/doi.org\/10.1177\/2045125320922474","journal-title":"Ther Adv Psychopharmacol"},{"key":"1460_CR50","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.jad.2020.04.013","volume":"273","author":"CL McGrory","year":"2020","unstructured":"McGrory CL, Ryan KM, Gallagher B, McLoughlin DM (2020) Vascular endothelial growth factor and pigment epithelial-derived factor in the peripheral response to ketamine. J Affect Disord 273:380\u2013383. https:\/\/doi.org\/10.1016\/j.jad.2020.04.013","journal-title":"J Affect Disord"},{"key":"1460_CR51","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1038\/s41398-020-00933-z","volume":"10","author":"Y Zhan","year":"2020","unstructured":"Zhan Y, Zhou Y, Zheng W, Liu W, Wang C, Lan X, Deng X, Xu Y, Zhang B, Ning Y (2020) Alterations of multiple peripheral inflammatory cytokine levels after repeated ketamine infusions in major depressive disorder. Transl Psychiatry 10:246. https:\/\/doi.org\/10.1038\/s41398-020-00933-z","journal-title":"Transl Psychiatry"},{"key":"1460_CR52","doi-asserted-by":"publisher","first-page":"204512532097379","DOI":"10.1177\/2045125320973794","volume":"10","author":"W Zheng","year":"2020","unstructured":"Zheng W, Zhou YL, Wang CY, Lan XF, Zhang B, Zhou SM, Yan S, Yang MZ, Nie S, Ning YP (2020) Association between plasma levels of bdnf and the antisuicidal effects of repeated ketamine infusions in depression with suicidal ideation. Ther Adv Psychopharmacol 10:2045125320973794. https:\/\/doi.org\/10.1177\/2045125320973794","journal-title":"Ther Adv Psychopharmacol"},{"key":"1460_CR53","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.jad.2020.06.068","volume":"276","author":"YL Zhou","year":"2020","unstructured":"Zhou YL, Wu FC, Wang CY, Zheng W, Lan XF, Deng XR, Ning YP (2020) Relationship between hippocampal volume and inflammatory markers following six infusions of ketamine in major depressive disorder. J Affect Disord 276:608\u2013615. https:\/\/doi.org\/10.1016\/j.jad.2020.06.068","journal-title":"J Affect Disord"},{"key":"1460_CR54","doi-asserted-by":"publisher","DOI":"10.47626\/2237-6089-2021-0298","author":"AT Caliman-Fontes","year":"2021","unstructured":"Caliman-Fontes AT, Leal GC, Correia-Melo FS, Paixao CS, Carvalho MS, Jesus-Nunes AP, Vieira F, Magnavita G, Bandeira ID, Mello RP, Beanes G, Silva SS, Echegaray M, Carvalho LP, Machado P, Sampaio AS, Cardoso TA, Kapczinski F, Lacerda ALT, Quarantini LC (2021) Brain-derived neurotrophic factor serum levels following ketamine and esketamine intervention for treatment-resistant depression: secondary analysis from a randomized trial. Trends Psychiatry Psychother. https:\/\/doi.org\/10.47626\/2237-6089-2021-0298","journal-title":"Trends Psychiatry Psychother"},{"key":"1460_CR55","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/j.jpsychires.2021.11.006","volume":"144","author":"MH Chen","year":"2021","unstructured":"Chen MH, Wu HJ, Li CT, Lin WC, Tsai SJ, Hong CJ, Tu PC, Bai YM, Mao WC, Su TP (2021) Is one or two infusions better in the first week of low-dose ketamine treatment for medication-resistant depression? A post hoc pooled analysis of randomized placebo-controlled and open-label trials. J Psychiatr Res 144:448\u2013454. https:\/\/doi.org\/10.1016\/j.jpsychires.2021.11.006","journal-title":"J Psychiatr Res"},{"key":"1460_CR56","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41398-021-01268-z","volume":"11","author":"JL Kruse","year":"2021","unstructured":"Kruse JL, Vasavada MM, Olmstead R, Hellemann G, Wade B, Breen EC, Brooks JO, Congdon E, Espinoza R, Narr KL, Irwin MR (2021) Depression treatment response to ketamine: sex-specific role of interleukin-8, but not other inflammatory markers. Transl Psychiatry 11:167. https:\/\/doi.org\/10.1038\/s41398-021-01268-z","journal-title":"Transl Psychiatry"},{"key":"1460_CR57","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1007\/s43440-020-00203-1","volume":"73","author":"M Wang","year":"2021","unstructured":"Wang M, Zhang B, Zhou Y, Wang C, Zheng W, Liu W, Zhan Y, Lan X, Ning Y (2021) Sleep improvement is associated with the antidepressant efficacy of repeated-dose ketamine and serum bdnf levels: a post-hoc analysis. Pharmacol Rep 73:594\u2013603. https:\/\/doi.org\/10.1007\/s43440-020-00203-1","journal-title":"Pharmacol Rep"},{"key":"1460_CR58","doi-asserted-by":"publisher","first-page":"e10989","DOI":"10.7717\/peerj.10989","volume":"9","author":"W Zheng","year":"2021","unstructured":"Zheng W, Zhou YL, Wang CY, Lan XF, Zhang B, Zhou SM, Yan S, Ning YP (2021) Plasma bdnf concentrations and the antidepressant effects of six ketamine infusions in unipolar and bipolar depression. PeerJ 9:e10989. https:\/\/doi.org\/10.7717\/peerj.10989","journal-title":"PeerJ"},{"key":"1460_CR59","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1186\/s12974-021-02245-5","volume":"18","author":"Y Zhou","year":"2021","unstructured":"Zhou Y, Wang C, Lan X, Li H, Chao Z, Ning Y (2021) Plasma inflammatory cytokines and treatment-resistant depression with comorbid pain: improvement by ketamine. J Neuroinflammation 18:200. https:\/\/doi.org\/10.1186\/s12974-021-02245-5","journal-title":"J Neuroinflammation"},{"key":"1460_CR60","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s11011-020-00547-w","volume":"35","author":"CS Cola\u00e7o","year":"2020","unstructured":"Cola\u00e7o CS, Alves SS, Nolli LM, Pinheiro WO, de Oliveira DGR, Santos BWL, Pic-Taylor A, Mortari MR, Caldas ED (2020) Toxicity of ayahuasca after 28 days daily exposure and effects on monoamines and brain-derived neurotrophic factor (bdnf) in brain of wistar rats. Metab Brain Dis 35:739\u2013751. https:\/\/doi.org\/10.1007\/s11011-020-00547-w","journal-title":"Metab Brain Dis"},{"key":"1460_CR61","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s00702-010-0451-2","volume":"117","author":"JJ Fortunato","year":"2010","unstructured":"Fortunato JJ, R\u00e9us GZ, Kirsch TR, Stringari RB, Fries GR, Kapczinski F, Hallak JE, Zuardi AW, Crippa JA, Quevedo J (2010) Chronic administration of harmine elicits antidepressant-like effects and increases bdnf levels in rat hippocampus. J Neural Transm (Vienna) 117:1131\u20131137. https:\/\/doi.org\/10.1007\/s00702-010-0451-2","journal-title":"J Neural Transm (Vienna)"},{"key":"1460_CR62","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1016\/j.pnpbp.2009.07.021","volume":"33","author":"JJ Fortunato","year":"2009","unstructured":"Fortunato JJ, R\u00e9us GZ, Kirsch TR, Stringari RB, Stertz L, Kapczinski F, Pinto JP, Hallak JE, Zuardi AW, Crippa JA, Quevedo J (2009) Acute harmine administration induces antidepressive-like effects and increases bdnf levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry 33:1425\u20131430. https:\/\/doi.org\/10.1016\/j.pnpbp.2009.07.021","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"1460_CR63","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41398-020-01011-0","volume":"10","author":"JA Morales-Garcia","year":"2020","unstructured":"Morales-Garcia JA, Calleja-Conde J, Lopez-Moreno JA, Alonso-Gil S, Sanz-SanCristobal M, Riba J, Perez-Castillo A (2020) N, n-dimethyltryptamine compound found in the hallucinogenic tea ayahuasca, regulates adult neurogenesis in vitro and in vivo. Transl Psychiatry 10:331. https:\/\/doi.org\/10.1038\/s41398-020-01011-0","journal-title":"Transl Psychiatry"},{"key":"1460_CR64","doi-asserted-by":"publisher","first-page":"5309","DOI":"10.1038\/s41598-017-05407-9","volume":"7","author":"JA Morales-Garc\u00eda","year":"2017","unstructured":"Morales-Garc\u00eda JA, de la Fuente RM, Alonso-Gil S, Rodr\u00edguez-Franco MI, Feilding A, Perez-Castillo A, Riba J (2017) The alkaloids of banisteriopsis caapi, the plant source of the amazonian hallucinogen ayahuasca, stimulate adult neurogenesis in vitro. Sci Rep 7:5309. https:\/\/doi.org\/10.1038\/s41598-017-05407-9","journal-title":"Sci Rep"},{"key":"1460_CR65","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/jcp.0000000000001396","volume":"41","author":"JM Rocha","year":"2021","unstructured":"Rocha JM, Rossi GN, de Lima OF, Bouso JC, de Oliveira SG, Yonamine M, Campos AC, Bertozi G, Cec\u00edlio Hallak JE, Dos Santos RG (2021) Effects of ayahuasca on the recognition of facial expressions of emotions in naive healthy volunteers: a pilot, proof-of-concept, randomized controlled trial. J Clin Psychopharmacol 41:267\u2013274. https:\/\/doi.org\/10.1097\/jcp.0000000000001396","journal-title":"J Clin Psychopharmacol"},{"key":"1460_CR66","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1097\/jcp.0000000000001428","volume":"41","author":"RG Dos Santos","year":"2021","unstructured":"Dos Santos RG, Os\u00f3rio FL, Rocha JM, Rossi GN, Bouso JC, Rodrigues LS, de Oliveira SG, Yonamine M, Hallak JEC (2021) Ayahuasca improves self-perception of speech performance in subjects with social anxiety disorder: a pilot, proof-of-concept, randomized, placebo-controlled trial. J Clin Psychopharmacol 41:540\u2013550. https:\/\/doi.org\/10.1097\/jcp.0000000000001428","journal-title":"J Clin Psychopharmacol"},{"key":"1460_CR67","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1021\/acsptsci.0c00099","volume":"4","author":"NRPW Hutten","year":"2021","unstructured":"Hutten NRPW, Mason NL, Dolder PC, Theunissen EL, Holze F, Liechti ME, Varghese N, Eckert A, Feilding A, Ramaekers JG, Kuypers KPC (2021) Low doses of lsd acutely increase bdnf blood plasma levels in healthy volunteers. ACS Pharmacol Transl Sci 4:461\u2013466. https:\/\/doi.org\/10.1021\/acsptsci.0c00099","journal-title":"ACS Pharmacol Transl Sci"},{"key":"1460_CR68","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1038\/s41386-020-00883-6","volume":"46","author":"F Holze","year":"2021","unstructured":"Holze F, Vizeli P, Ley L, M\u00fcller F, Dolder P, Stocker M, Duthaler U, Varghese N, Eckert A, Borgwardt S, Liechti ME (2021) Acute dose-dependent effects of lysergic acid diethylamide in a double-blind placebo-controlled study in healthy subjects. Neuropsychopharmacology 46:537\u2013544. https:\/\/doi.org\/10.1038\/s41386-020-00883-6","journal-title":"Neuropsychopharmacology"},{"key":"1460_CR69","doi-asserted-by":"publisher","first-page":"e2020705118","DOI":"10.1073\/pnas.2020705118","volume":"118","author":"D De Gregorio","year":"2021","unstructured":"De Gregorio D, Popic J, Enns JP, Inserra A, Skalecka A, Markopoulos A, Posa L, Lopez-Canul M, Qianzi H, Lafferty CK, Britt JP, Comai S, Aguilar-Valles A, Sonenberg N, Gobbi G (2021) Lysergic acid diethylamide (lsd) promotes social behavior through mtorc1 in the excitatory neurotransmission. Proc Natl Acad Sci 118:e2020705118. https:\/\/doi.org\/10.1073\/pnas.2020705118","journal-title":"Proc Natl Acad Sci"},{"key":"1460_CR70","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1038\/s41386-019-0569-3","volume":"45","author":"F Holze","year":"2020","unstructured":"Holze F, Vizeli P, M\u00fcller F, Ley L, Duerig R, Varghese N, Eckert A, Borgwardt S, Liechti ME (2020) Distinct acute effects of lsd, mdma, and d-amphetamine in healthy subjects. Neuropsychopharmacology 45:462\u2013471. https:\/\/doi.org\/10.1038\/s41386-019-0569-3","journal-title":"Neuropsychopharmacology"},{"key":"1460_CR71","doi-asserted-by":"publisher","first-page":"60","DOI":"10.3389\/fphar.2019.00060","volume":"10","author":"Z Deng","year":"2019","unstructured":"Deng Z, Deng S, Zhang MR, Tang MM (2019) Fibroblast growth factors in depression. Front Pharmacol 10:60. https:\/\/doi.org\/10.3389\/fphar.2019.00060","journal-title":"Front Pharmacol"},{"key":"1460_CR72","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1007\/s00406-018-0919-x","volume":"268","author":"KM Ryan","year":"2018","unstructured":"Ryan KM, McLoughlin DM (2018) Vascular endothelial growth factor plasma levels in depression and following electroconvulsive therapy. Eur Arch Psychiatry Clin Neurosci 268:839\u2013848. https:\/\/doi.org\/10.1007\/s00406-018-0919-x","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1460_CR73","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.psyneuen.2015.07.002","volume":"62","author":"AF Carvalho","year":"2015","unstructured":"Carvalho AF, K\u00f6hler CA, McIntyre RS, Kn\u00f6chel C, Brunoni AR, Thase ME, Quevedo J, Fernandes BS, Berk M (2015) Peripheral vascular endothelial growth factor as a novel depression biomarker: a meta-analysis. Psychoneuroendocrinology 62:18\u201326. https:\/\/doi.org\/10.1016\/j.psyneuen.2015.07.002","journal-title":"Psychoneuroendocrinology"},{"key":"1460_CR74","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1016\/j.euroneuro.2015.06.001","volume":"25","author":"PT Tseng","year":"2015","unstructured":"Tseng PT, Cheng YS, Chen YW, Wu CK, Lin PY (2015) Increased levels of vascular endothelial growth factor in patients with major depressive disorder: a meta-analysis. Eur Neuropsychopharmacol 25:1622\u20131630. https:\/\/doi.org\/10.1016\/j.euroneuro.2015.06.001","journal-title":"Eur Neuropsychopharmacol"},{"key":"1460_CR75","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1177\/0004867419893433","volume":"54","author":"A Rigal","year":"2020","unstructured":"Rigal A, Colle R, Asmar KE, Trabado S, Loeb E, Martin S, Choucha W, Gressier F, Costemale-Lacoste JF, de Larminat D, Deflesselle E, F\u00e8ve B, Chanson P, Becquemont L, Verstuyft C, Corruble E (2020) Lower plasma vascular endothelial growth factor a in major depressive disorder not normalized after antidepressant treatment: a case control study. Aust N Z J Psychiatry 54:402\u2013408. https:\/\/doi.org\/10.1177\/0004867419893433","journal-title":"Aust N Z J Psychiatry"},{"key":"1460_CR76","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1021\/acsptsci.0c00063","volume":"4","author":"TW Flanagan","year":"2021","unstructured":"Flanagan TW, Billac GB, Landry AN, Sebastian MN, Cormier SA, Nichols CD (2021) Structure-activity relationship analysis of psychedelics in a rat model of asthma reveals the anti-inflammatory pharmacophore. ACS Pharmacol Transl Sci 4:488\u2013502. https:\/\/doi.org\/10.1021\/acsptsci.0c00063","journal-title":"ACS Pharmacol Transl Sci"},{"key":"1460_CR77","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1080\/09540261.2018.1481827","volume":"30","author":"TW Flanagan","year":"2018","unstructured":"Flanagan TW, Nichols CD (2018) Psychedelics as anti-inflammatory agents. Int Rev Psychiatry 30:363\u2013375. https:\/\/doi.org\/10.1080\/09540261.2018.1481827","journal-title":"Int Rev Psychiatry"},{"key":"1460_CR78","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1017\/s0033291719001454","volume":"49","author":"EF Osimo","year":"2019","unstructured":"Osimo EF, Baxter LJ, Lewis G, Jones PB, Khandaker GM (2019) Prevalence of low-grade inflammation in depression: a systematic review and meta-analysis of crp levels. Psychol Med 49:1958\u20131970. https:\/\/doi.org\/10.1017\/s0033291719001454","journal-title":"Psychol Med"},{"key":"1460_CR79","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1192\/bjp.2018.66","volume":"214","author":"SR Chamberlain","year":"2019","unstructured":"Chamberlain SR, Cavanagh J, de Boer P, Mondelli V, Jones DNC, Drevets WC, Cowen PJ, Harrison NA, Pointon L, Pariante CM, Bullmore ET (2019) Treatment-resistant depression and peripheral c-reactive protein. Br J Psychiatry 214:11\u201319. https:\/\/doi.org\/10.1192\/bjp.2018.66","journal-title":"Br J Psychiatry"},{"key":"1460_CR80","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1016\/j.jad.2019.07.045","volume":"257","author":"C Yang","year":"2019","unstructured":"Yang C, Wardenaar KJ, Bosker FJ, Li J, Schoevers RA (2019) Inflammatory markers and treatment outcome in treatment resistant depression: a systematic review. J Affect Disord 257:640\u2013649. https:\/\/doi.org\/10.1016\/j.jad.2019.07.045","journal-title":"J Affect Disord"},{"key":"1460_CR81","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.bbi.2015.06.001","volume":"49","author":"R Haapakoski","year":"2015","unstructured":"Haapakoski R, Mathieu J, Ebmeier KP, Alenius H, Kivim\u00e4ki M (2015) Cumulative meta-analysis of interleukins 6 and 1\u03b2, tumour necrosis factor \u03b1 and c-reactive protein in patients with major depressive disorder. Brain Behav Immun 49:206\u2013215. https:\/\/doi.org\/10.1016\/j.bbi.2015.06.001","journal-title":"Brain Behav Immun"},{"key":"1460_CR82","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1007\/s00441-018-02985-6","volume":"377","author":"T Rantam\u00e4ki","year":"2019","unstructured":"Rantam\u00e4ki T (2019) Trkb neurotrophin receptor at the core of antidepressant effects, but how? Cell Tissue Res 377:115\u2013124. https:\/\/doi.org\/10.1007\/s00441-018-02985-6","journal-title":"Cell Tissue Res"},{"key":"1460_CR83","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1111\/pcn.12299","volume":"69","author":"H Kunugi","year":"2015","unstructured":"Kunugi H, Hori H, Ogawa S (2015) Biochemical markers subtyping major depressive disorder. Psychiatry Clin Neurosci 69:597\u2013608. https:\/\/doi.org\/10.1111\/pcn.12299","journal-title":"Psychiatry Clin Neurosci"},{"key":"1460_CR84","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.1007\/s00213-018-4950-4","volume":"235","author":"MJF Levy","year":"2018","unstructured":"Levy MJF, Boulle F, Steinbusch HW, van den Hove DLA, Kenis G, Lanfumey L (2018) Neurotrophic factors and neuroplasticity pathways in the pathophysiology and treatment of depression. Psychopharmacology 235:2195\u20132220. https:\/\/doi.org\/10.1007\/s00213-018-4950-4","journal-title":"Psychopharmacology"},{"key":"1460_CR85","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.neuroscience.2013.04.060","volume":"246","author":"JC Felger","year":"2013","unstructured":"Felger JC, Lotrich FE (2013) Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience 246:199\u2013229. https:\/\/doi.org\/10.1016\/j.neuroscience.2013.04.060","journal-title":"Neuroscience"},{"key":"1460_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1152\/physrev.1999.79.1.1","volume":"79","author":"AV Turnbull","year":"1999","unstructured":"Turnbull AV, Rivier CL (1999) Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. Physiol Rev 79:1\u201371. https:\/\/doi.org\/10.1152\/physrev.1999.79.1.1","journal-title":"Physiol Rev"},{"key":"1460_CR87","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.neuroscience.2012.09.017","volume":"239","author":"F Jeanneteau","year":"2013","unstructured":"Jeanneteau F, Chao MV (2013) Are bdnf and glucocorticoid activities calibrated? Neuroscience 239:173\u2013195. https:\/\/doi.org\/10.1016\/j.neuroscience.2012.09.017","journal-title":"Neuroscience"},{"key":"1460_CR88","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1440-1819.2010.02135.x","volume":"64","author":"H Kunugi","year":"2010","unstructured":"Kunugi H, Hori H, Adachi N, Numakawa T (2010) Interface between hypothalamic-pituitary-adrenal axis and brain-derived neurotrophic factor in depression. Psychiatry Clin Neurosci 64:447\u2013459. https:\/\/doi.org\/10.1111\/j.1440-1819.2010.02135.x","journal-title":"Psychiatry Clin Neurosci"},{"key":"1460_CR89","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1016\/j.neurobiolaging.2007.02.027","volume":"29","author":"L Tong","year":"2008","unstructured":"Tong L, Balazs R, Soiampornkul R, Thangnipon W, Cotman CW (2008) Interleukin-1 beta impairs brain derived neurotrophic factor-induced signal transduction. Neurobiol Aging 29:1380\u20131393. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2007.02.027","journal-title":"Neurobiol Aging"},{"key":"1460_CR90","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1046\/j.1365-2141.1999.01543.x","volume":"106","author":"B Jilma","year":"1999","unstructured":"Jilma B, Hergovich N, Stohlawetz P, Eichler HG, Bauer P, Wagner OF (1999) Circadian variation of granulocyte colony stimulating factor levels in man. Br J Haematol 106:368\u2013370. https:\/\/doi.org\/10.1046\/j.1365-2141.1999.01543.x","journal-title":"Br J Haematol"},{"key":"1460_CR91","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1016\/0026-0495(81)90094-9","volume":"30","author":"E Canalis","year":"1981","unstructured":"Canalis E (1981) Effect of platelet-derived growth factor on DNA and protein synthesis in cultured rat calvaria. Metabolism 30:970\u2013975. https:\/\/doi.org\/10.1016\/0026-0495(81)90094-9","journal-title":"Metabolism"},{"key":"1460_CR92","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1093\/bja\/aev135","volume":"115","author":"N Khalili-Mahani","year":"2015","unstructured":"Khalili-Mahani N, Martini CH, Olofsen E, Dahan A, Niesters M (2015) Effect of subanaesthetic ketamine on plasma and saliva cortisol secretion. Br J Anaesth 115:68\u201375. https:\/\/doi.org\/10.1093\/bja\/aev135","journal-title":"Br J Anaesth"},{"key":"1460_CR93","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2018.00185","author":"ACdM Galv\u00e3o","year":"2018","unstructured":"Galv\u00e3o ACdM, de Almeida RN, Silva EAdS, Freire FAM, Palhano-Fontes F, Onias H, Arcoverde E, Maia-de-Oliveira JP, de Ara\u00fajo DB, Lob\u00e3o-Soares B, Galv\u00e3o-Coelho NL (2018) Cortisol modulation by ayahuasca in patients with treatment resistant depression and healthy controls. Front Psych. https:\/\/doi.org\/10.3389\/fpsyt.2018.00185","journal-title":"Front Psych"},{"key":"1460_CR94","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1093\/ijnp\/pyaa087","volume":"24","author":"B Kadriu","year":"2021","unstructured":"Kadriu B, Greenwald M, Henter ID, Gilbert JR, Kraus C, Park LT, Zarate CA (2021) Ketamine and serotonergic psychedelics: common mechanisms underlying the effects of rapid-acting antidepressants. Int J Neuropsychopharmacol 24:8\u201321. https:\/\/doi.org\/10.1093\/ijnp\/pyaa087","journal-title":"Int J Neuropsychopharmacol"},{"key":"1460_CR95","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1007\/s13346-017-0476-2","volume":"8","author":"M Le Nedelec","year":"2018","unstructured":"Le Nedelec M, Glue P, Winter H, Goulton C, Broughton L, Medlicott N (2018) Acute low-dose ketamine produces a rapid and robust increase in plasma bdnf without altering brain bdnf concentrations. Drug Deliv Transl Res 8:780\u2013786. https:\/\/doi.org\/10.1007\/s13346-017-0476-2","journal-title":"Drug Deliv Transl Res"},{"key":"1460_CR96","doi-asserted-by":"publisher","first-page":"576135","DOI":"10.3389\/fpsyt.2020.576135","volume":"11","author":"M Li","year":"2020","unstructured":"Li M, Xie A, Liu Y, Zeng Q, Huang S, Huang Q, Shao T, Chen X, Liao Z, Cai Y, Xiao Z, Zhang X, Shen H (2020) Ketamine administration leads to learning-memory dysfunction and decreases serum brain-derived neurotrophic factor in rats. Front Psychiatry 11:576135. https:\/\/doi.org\/10.3389\/fpsyt.2020.576135","journal-title":"Front Psychiatry"},{"key":"1460_CR97","doi-asserted-by":"publisher","first-page":"9655","DOI":"10.1038\/s41598-019-45976-5","volume":"9","author":"AK Gejl","year":"2019","unstructured":"Gejl AK, Enevold C, Bugge A, Andersen MS, Nielsen CH, Andersen LB (2019) Associations between serum and plasma brain-derived neurotrophic factor and influence of storage time and centrifugation strategy. Sci Rep 9:9655. https:\/\/doi.org\/10.1038\/s41598-019-45976-5","journal-title":"Sci Rep"}],"container-title":["European Archives of Psychiatry and Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-022-01460-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00406-022-01460-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00406-022-01460-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T05:17:28Z","timestamp":1677215848000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00406-022-01460-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,13]]},"references-count":97,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["1460"],"URL":"https:\/\/doi.org\/10.1007\/s00406-022-01460-2","relation":{},"ISSN":["0940-1334","1433-8491"],"issn-type":[{"value":"0940-1334","type":"print"},{"value":"1433-8491","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,13]]},"assertion":[{"value":"5 April 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}